What is the Evidence Supporting Antenatal IVIG Therapy?
The use of antenatal IVIG therapy is supported by various studies and clinical trials. For instance, research has shown that IVIG administration can significantly reduce the incidence of intracranial hemorrhage in fetuses affected by alloimmune thrombocytopenia. Similarly, in cases of HDFN, IVIG has been shown to reduce the need for invasive treatments and improve fetal outcomes.
